Achieve Life Sciences, Inc. (ACHV)

NCM – Цена в реальном времени. Валюта: USD

6.02

+0.32 (5.61%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

5.94

-0.08 (-1.33%)

После закрытия: Jun 26, 2026, 7:56 PM EDT

02.06.2026

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch

19.05.2026

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of continuous exposure¹ SEATTLE and VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced the presentation of comprehensive long-term safety data from the ORCA-OL study at the American Thoracic Society (ATS) 2026 Annual Meeting. Additional cytisinicline data will be presented at ATS on May 20.

13.05.2026

Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission

Achieve Life Sciences (ACHV) is downgraded to 'Hold' due to anticipated CRL of cytisinicline for smoking cessation and NDA resubmission in Q4 2026. FDA inspection issues at a third-party manufacturer will trigger a Complete Response Letter on or before June 20,2026, pushing NDA resubmission to Q4 2026 and potential launch H1 2027. Company has shifted cytisinicline supply to Adare, but future FDA inspections at Adare's facility remain a key risk for approval timelines.

12.05.2026

Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript

12.05.2026

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences NASDAQ: ACHV used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027.

12.05.2026

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of Sales, reuniting the team behind the launch of Ohtuvayre®, one of the most successful specialty pharmaceutical launches in recent industry history Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of Sales, reuniting the team behind the launch of Ohtuvayre®, one of the most successful specialty pharmaceutical launches in recent industry history

12.05.2026

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U . S . -based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the first quarter of 2026 and provided corporate highlights, including the recent financing and leadership updates.

Видео

No Data

There is no data to display

Пресс-релизы

02.06.2026

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

19.05.2026

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

12.05.2026

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

12.05.2026

Achieve Life Sciences, Inc. (ACHV)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Achieve Life Sciences, Inc. (ACHV)

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission

Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission

Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Search stocks

Achieve Life Sciences, Inc. (ACHV)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Achieve Life Sciences, Inc. (ACHV)

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission

Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission

Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates